Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions.

A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers ... with asthma and COPD under a 510 ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Certain medications commonly used to treat asthma and COPD can damage the environment and worsen respiratory issues. KYW ...

Individuals with asthma and chronic obstructive pulmonary disease (COPD) were more vulnerable than ... Microplastic fibers present in the ambient air can be inhaled into the lungs and promote ...

The demand for inhalation and nasal spray generic drugs is growing as these medications provide affordable and effective treatment options for respiratory ailments like asthma, COPD, and allergies.

The global Respiratory Care Devices Market is valued at $23.93 billion in 2024 and is projected to reach a value of $54.38 ...

Asthma Quality of Life Questionnaire; AUC: Area under the curve; COPD: Chronic obstructive pulmonary disease; FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity; ICS: Inhaled ...

OhtuvayreTM (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines ... cystic fibrosis, asthma and other ...

In today’s fast-paced world, many individuals struggle with respiratory issues, whether due to chronic conditions like asthma and COPD or temporary ... on pharmaceutical inhalers or steroids.

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...